Arch Venture Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Arch Venture Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$1.77M	Sell	20,000 -20,000	-50%	-$2.27M	8.83%	3
2020 Q2	$4.26M	Sell	40,000 -266,382	-87%	-$23.9M	14.35%	3
2020 Q1	$18.2M	Sell	306,382 -25,000	-8%	-$1.7M	30.67%	2
2019 Q4	$22.9M	Sell	331,382 -54,123	-14%	-$3.28M	29.84%	2
2019 Q3	$40M	Buy	+385,505	New	+$36.4M	43.8%	1

Other funds holding SYRS

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Arch Venture Management's SYRS Position: Q3 2020 in Review

Arch Venture Management reduced its Syros Pharmaceuticals, Inc. Common Stock (SYRS) stake by 50% in Q3 2020, selling an estimated $2.27M and leaving 20,000 shares worth $1.77M. The position accounts for 8.83% of the portfolio, ranked #3.

Arch Venture Management first reported a position in SYRS in Q3 2019 and has held it in 5 quarters since. The position peaked at $40M in Q3 2019. 93 funds tracked by Wall St. Rank hold SYRS as of Q3 2020.

Arch Venture Management held 20,000 shares of Syros Pharmaceuticals, Inc. Common Stock worth $1.77M as of Q3 2020.
Arch Venture Management sold 20,000 Syros Pharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $2.27M.
Syros Pharmaceuticals, Inc. Common Stock made up 8.83% of Arch Venture Management's portfolio in Q3 2020, its #3 holding.
Arch Venture Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2019 and has held it in 5 quarters since.
Arch Venture Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $40M in Q3 2019.
93 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on Arch Venture Management's 13F filing for Q3 2020, filed 16 Nov 2020.